Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01412151 · ClinicalTrials.gov registry record · Phase 2
Creatine Safety & Tolerability in Huntington's Disease
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01412151: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01412151 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01412151, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
Interventions
- DRUG Creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01412151
The ClinicalTrials.gov registry entry for NCT01412151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatine monohydrate is the first listed.
NCT01412151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01412151 about?
NCT01412151 is a clinical study titled "Creatine Safety & Tolerability in Huntington's Disease". The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
What is the current status of trial NCT01412151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2005-04. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01412151?
The interventions under investigation include: Creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT01412151?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.